Helix BioPharma Corp., a clinical-stage oncology company, announced the appointment of Zachary T. Stadnyk to its Board of Directors and Natalia L. Butterworth as Corporate Secretary, effective immediately. Stadnyk, a former TSX Life Sciences Lead, brings over 15 years of experience in biotechnology, capital markets, and public company leadership. Butterworth, a seasoned corporate governance professional, has over 15 years of experience supporting companies in governance and regulatory compliance across multiple jurisdictions.
The appointments come as Helix advances its capital markets strategy, including preparations for a planned Nasdaq listing through the Multijurisdictional Disclosure System (MJDS). The Company is also relocating its registered and records office from Toronto, Ontario to Vancouver, British Columbia to align with its governance and capital markets infrastructure.
Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix BioPharma, stated, "As Helix continues to execute on its corporate and clinical development objectives, strengthening our capital markets and governance capabilities remains a key priority. These appointments come at an important time for Helix as we finalize the clinical protocol for L-DOS47 and actively prepare for a Nasdaq listing under the MJDS."
Stadnyk has led and supported over $100 million in institutional financings and contributed to strategic transactions, including the $435 million acquisition of The Supreme Cannabis Company by Canopy Growth. He expressed excitement about joining Helix at a pivotal stage, noting the Company's differentiated approach to addressing the tumor microenvironment and its clear path toward a Nasdaq listing.
Helix's pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer. The Company also advances two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator, and GEMCEDA, a first-in-class oral gemcitabine prodrug.
For more information, visit https://www.helixbiopharma.com/.
